IP Verse

Sodium Chloride Solution For Drug Reconstitution Or Dilution - EP3225233

The patent EP3225233 was granted to Wyeth on Aug 14, 2019. The application was originally filed on Oct 27, 2006 under application number EP17166616A. The patent is currently recorded with a legal status of "Revoked".

EP3225233

WYETH
Application Number
EP17166616A
Filing Date
Oct 27, 2006
Status
Revoked
Jul 15, 2022
Grant Date
Aug 14, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BIOVERATIV THERAPEUTICSMay 14, 2020ZWICKER -
SWEDISH ORPHAN BIOVITRUMMay 14, 2020AWA SWEDEN -

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS6372716
OPPOSITIONEP0041173
OPPOSITIONEP3225233
OPPOSITIONUS3717708
OPPOSITIONWO2005058283
OPPOSITIONWO2005089712
OPPOSITIONWO2007053533
SEARCHUS2001031721
SEARCHUS3717708
SEARCHWO2005058283
SEARCHWO2005089712

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- MORRIS, M.W. ET AL., "Basic examination of blood", MORRIS, M.W. ET AL., HENRY, J.B., Clinical Diagnosis and Management by Laboratory Methods, WB SAUNDERS, (2001), pages 479 - 519-
OPPOSITION- anonymous, "BeneFIX - Nonacog alfa", Commission of the European Communities, (19970827), pages 1 - 57-
OPPOSITION- Anonymous, "BeneFIX - Nonacog alfa", Commission of the European Communities, (1997), pages 1 - 57-
OPPOSITION- Anonymous, "Research and development", International Blood/Plamsa News, (20010401), vol. 18, no. 9, page 127, XP055739338-
OPPOSITION- A T Florence, Et Al, "Clinical relevance of osmotic effects", Physicochemical Principles of Pharmacy, macMillan Press LTD, (19880101), pages 59 - 60, XP055739360-
OPPOSITION- CHAI et al., "Effects on Erythrocyte Aggregation and Blood Coagulation from Iohexol Solutions with and without Sodium Chloride", Acta Radiologica, (19950000), vol. 36, pages 204 - 209, XP055609707-
OPPOSITION- Ernst Mutschler, Et Al, "Applikation", Arzneimittelwirkungen Lehrbuch der Pharmakologie und Toxikologie, (19970101), pages 6 - 8, XP055739350-
OPPOSITION- Henry R Constantino, Et Al, "Excipients for use in Lyophilized Pharmaceutical Bioproducts", Lyophilization of Biopharmaceuticals, (20040101), pages 197 - 198, XP055739344-
OPPOSITION- Howard Kutchai, "OSMOSIS (A self-instructional package", Department of Molecular Physiology & Biological Physics University of Virginia School of Medicine, (20030101), pages 1 - 17, XP055739353-
SEARCH- BUSH L ET AL, "THE FORMULATION OF RECOMBINANT FACTOR IX: STABILITY, ROBUSTNESS, AND CONVENIENCE", SEMINARS IN HEMATOLOGY, PHILADELPHIA, PA, US, (199804), vol. 35, no. 2, SUPPL 2, ISSN 0037-1963, pages 18 - 21, XP001010494 [A] 1-19 * the whole document * * page 19, column r, line 16 - line 26 * * figures 2,3 *-
SEARCH- VAN DEN BERG H M ET AL, "BeneFixTM induces agglutination of red cells", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, (20001116), vol. 96, no. 11 Part 1, ISSN 0006-4971, page 641a, XP008083763 [A] 1-19 * abstract *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents